Evommune (EVMN) Liabilities and Shareholders Equity (2024 - 2026)

Evommune (EVMN) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $322.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $322.5 million; the TTM figure through Mar 2026 stood at $631.9 million (changed N/A YoY), while the FY2025 annual figure was $224.9 million, up 195.77% from the prior year.
• Liabilities and Shareholders Equity grew to $322.5 million in Q1 2026 per EVMN's latest filing, from $224.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $322.5 million in Q1 2026 and bottomed at $76.1 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $177.0 million across 3 years, with a median of $154.7 million in 2025.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 195.77% in 2025 and fell as far as 195.77% in 2025.
• Evommune's Liabilities and Shareholders Equity stood at $76.1 million in 2024, then jumped by 195.77% to $224.9 million in 2025, then soared by 43.35% to $322.5 million in 2026.
• Business Quant data shows EVMN's Liabilities and Shareholders Equity at $322.5 million in Q1 2026, $224.9 million in Q4 2025, and $84.5 million in Q3 2025.